Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.49 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.49 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9119656 | 1.00 | PTGS2 (0.49) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL1394339 | 1.00 | PTGS2 (0.49) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL4483212 | 0.89 | GABRA1 (0.47) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL4480628 | 0.89 | GABRA1 (0.47) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL5016325 | 0.89 | GABRA1 (0.47) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| Ibuprofen SCHEMBL1891683 | 0.88 | PTGS2 (0.71) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL5960824 | 0.86 | GABRA1 (0.42) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL5017117 | 0.86 | GABRA1 (0.42) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL10429886 | 0.86 | CYP2D6 (0.47) | PTGS2PTGS1CYP2C9CXCL8MMP1 | |
| SCHEMBL5983552 | 0.85 | PTGS2 (0.46) | PTGS2PTGS1LMNAAKR1C3CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | disclosed |
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | disclosed |
| US-5380927-A | Process for preparing optically active 2-aryl-alkanoic acids, in particular 2-aryl-propionic acids | MEDICE CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) | 1995-01-10 | — | — | US | disclosed |
| US-5266723-A | Process for the preparation of optically active 2-aryl-alkanoic acids, especially 2-aryl-propionic acids | MEDICE, LTD., CHEM.-PHARM. FABRIK PUTTER GMBH & CO. KG (DE) | 1993-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | CXCL8, MMP8, CCR8 | PTGS2 219/4885PTGS1 171/4885LMNA 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.